Metraipolis › archive › dc_5017f4e89180

Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression — Europe PMC PMID:41226553

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41226553
DOI
10.3390/ijms262110515
License (as archived)
solo-consultazione
Archived
2026-11-08T23:44:22.416Z
SHA-256 of the archived text
fa5b6163d89e2082791b1308a319c4f9a43b191789bec77eb95423f356d1e773
Stable URL of this page
https://metraipolis.com/documento/dc_5017f4e89180

How to cite

Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression — Europe PMC PMID:41226553 — Europe PMC (en), https://europepmc.org/article/MED/41226553 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5017f4e89180 (Metraipolis archive dc_5017f4e89180, sha256 fa5b6163d89e2082791b1308a319c4f9a43b191789bec77eb95423f356d1e773)
BibTeX
@misc{dc5017f4e89180,
  title = {Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression — Europe PMC PMID:41226553},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41226553},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5017f4e89180; sha256 fa5b6163d89e2082791b1308a319c4f9a43b191789bec77eb95423f356d1e773},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41226553. Agents can read the archived copy with the MCP tool read_document.